诺华Rhapsido在二期食物过敏试验数据中展现潜力。
Novartis' Rhapsido shows promise in Phase 2 food allergy data
生命科学资讯
生物技术与制药领域的最新动态
诺华斥资2.7亿美元收购Avidity，获得两项临床前心血管候选药物，心房项目应运而生。
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
诺华与武田将参与下一轮医保药品价格谈判。
Novartis, Takeda to enter next Medicare drug price negotiations
欧洲药品管理局推荐Moderna流感-新冠联合疫苗及诺华荨麻疹药片。
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
诺华完成Avidity交易，罕见心脏病业务分拆启动。
Novartis closes Avidity deal as rare heart disease spinout launches
诺华将再建放射性配体工厂；德国加强对格瑞克海默的调查。
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Madrigal股价遭遇抛售；前诺华高管转投第一三共。
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
诺华将以1.59亿美元向私募股权财团出售印度子公司。
Novartis to divest India unit to private equity-led consortium for $159M
第一三共任命前诺华首席医学官蔡约翰执掌研发部门。
Daiichi picks former Novartis CMO John Tsai to head up R&D
诺华因疗效不足终止一期实体瘤项目。
Novartis winds down ph. 1 solid tumor program after lacking efficacy
诺华与环肽生物技术公司达成逾17亿美元心血管药物合作协议。
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
更新：诺华与Unnatural Products签署大环化合物合作协议
Updated: Novartis signs macrocyclic deal with Unnatural Products
诺华与Unnatural Products签署大环化合物协议，预付款达1亿美元。
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
礼来Zepbound与Taltz联合疗法公布银屑病与减重数据；诺华强化Rhapsido疗效结果。
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
诺华调整早期研发管线：剔除6个项目，新增2个癌症候选药物。
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
诺华预计仿制药将削减2026年销售额40亿美元。
Novartis says generics to erode $4B from 2026 sales
诺华发现新型CDK抑制剂。
Novartis discovers new CDK inhibitors
诺华以5000万美元预付款从中国生物技术公司获得放射性药物资产许可。
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
诺华与SciNeuro合作开发阿尔茨海默病临床前靶向淀粉样蛋白药物
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
诺华将在佛罗里达州建立第四家美国放射治疗工厂。
Novartis to build fourth US radiotherapy factory in Florida